ロード中...
Strategies to circumvent the T315I gatekeeper mutation in the Bcr-Abl tyrosine kinase
Despite the remarkable success of imatinib against Bcr-Abl, development of secondary resistance, most often due to point mutations in the Bcr-Abl tyrosine kinase (TK) domain, is quite common. Of these, the T315I “gatekeeper” mutation is resistant to all currently registered Bcr-Abl TK inhibitors (TK...
保存先:
| 主要な著者: | , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Elsevier
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3747003/ https://ncbi.nlm.nih.gov/pubmed/23977454 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.lrr.2013.02.001 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|